Aryl-Quinolin Linker-Payload for Targeted Antibody Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges such as genetic polymorphisms, non-specific drug action, and drug resistance, limiting the effectiveness of conventional therapies.
Innovation Solution
Development of a linker-payload composed of an aryl-quinolin derivative connected to a linking group, which is further conjugated to an antibody to form an antibody-drug conjugate, enhancing drug concentration at the target tissue and broadening the therapeutic window.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat cancer, then cancer cells can be killed, but non-specific drug action causes damage to normal tissues and limits treatment effectiveness
Solution Approach 1:
The drug delivery system is segmented into three functional components: (1) an antibody that specifically recognizes and binds to cancer cell surface antigens, (2) a linker that connects the antibody to the cytotoxic payload and remains stable in circulation, and (3) a cytotoxic payload that is released only after internalization into the cancer cell. This segmentation allows the drug to be delivered specifically to target tissues while minimizing exposure to normal tissues, thereby resolving the contradiction between treatment effectiveness and non-specific toxicity.
Solution Approach 2:
The antibody acts as an intermediary that mediates the delivery of the cytotoxic payload to cancer cells. Instead of administering the toxic drug directly, the antibody serves as a carrier that specifically transports the drug to the target site through antigen-antibody binding, followed by internalization. This intermediary mechanism enables selective drug delivery to cancer cells while protecting normal tissues from drug exposure, thus resolving the contradiction between killing cancer cells and avoiding damage to normal tissues.
2Reliability
If drug concentration is increased to overcome drug resistance, then treatment efficacy improves, but therapeutic window narrows due to increased toxicity
Solution Approach 1:
The ADC achieves local quality by concentrating the cytotoxic payload specifically at the cancer cell location through antibody-mediated targeting. The high drug concentration is localized to the tumor site where the antibody binds to its antigen, while normal tissues receive minimal or no drug exposure. This local concentration strategy allows achieving high effective doses at the target site without proportionally increasing systemic toxicity, thereby maintaining a wide therapeutic window while overcoming drug resistance.
Solution Approach 2:
The invention changes the distribution parameter of the drug from systemic to localized delivery. By using the antibody-drug conjugate structure, the drug concentration parameter is dramatically increased at the target site (cancer cells) while remaining low in normal tissues. This parameter change in drug distribution enables achieving high local concentrations necessary to overcome drug resistance without narrowing the therapeutic window, as the systemic exposure remains low.
3Adaptability or versatility
If aryl-quinolin derivatives are developed as standalone oral drugs, then they show antitumor activity, but their potential as antibody-drug conjugates remains unexplored
Solution Approach 1:
The aryl-quinolin derivative is designed with multi-functionality: it can serve as (1) a standalone oral anticancer drug that inhibits TRAP1, (2) a cytotoxic payload for antibody-drug conjugates when equipped with appropriate linker attachment groups, and (3) a compound that can be optimized for both oral bioavailability and ADC stability. This universal design allows the same core chemical structure to be applied in multiple therapeutic formats, expanding its adaptability while managing complexity through modular chemical design.
Data Source
AI summary
The present disclosure provides a linker-payload being effective in treating a cancer, wherein the linker-payload is made by connecting a linking group to a specific site of an aryl-quinolin derivative having a structure of the following Formula (I):The present disclosure also relates to an antibody-drug conjugate made by further conjugating the aforementioned linker-payload to an antibody, and uses of the linker-payload and antibody-drug conjugate.